FibroGen stockholders approve 2024 Equity Incentive Plan and elect directors

KYNTRA BIO, INC.

Class I directors elected: Thane Wettig (54.9M for), James Schoeneck (53.1M for), Maykin Ho (53.6M for).
2024 Equity Incentive Plan approved: 44.3M for, 10.8M against; plan adds 2.2M new shares plus prior plan reserve.
Advisory vote on executive compensation approved: 53.5M for, 1.75M against.
PricewaterhouseCoopers ratified as independent auditor for 2024: 72.5M for, 0.2M against.
Say-on-pay frequency: every year preferred (54.8M votes).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.